BIIB

Biogen
D

BIIB

Arincen57/100B

Biogen cash flow statement 1989–2026

In fiscal year 2025 Biogen spent 0.00 USD buying back its shares and paid 0.00 USD in dividends: 0.00 USD in all. That is 0% of its free cash flow.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Net income
-69.50M1.29B1.63B1.16B2.96B1.73B4.06B5.89B4.47B2.67B3.70B
Depreciation and amortization
881.80M779.90M673.20M494.80M518.40M487.70M457.20M464.70M650.50M721.60M682.70M
Stock-based compensation
141.10M290.80M291.20M264.20M254.10M238.60M198.30M182.30M157.50M128.00M154.80M
Change in working capital
-398.90M-1.06B-155.20M-648.70M-890.30M-145.50M-187.20M199.30M400.20M235.40M73.00M
Change in receivables
-20.70M42.10M194.20M56.70M-222.40M326.00M179.50M5.50M-199.50M-667.60M-227.50M
Change in inventory
-101.60M-64.70M-273.80M-130.90M-320.20M-462.40M-316.30M-19.20M-52.10M-94.50M-165.60M
Change in payables
—0.000.000.000.000.000.000.000.000.000.00
Change in other working capital
-276.60M-1.04B-75.60M-574.50M-347.70M-9.10M-50.40M213.00M651.80M997.50M466.10M
Other non-cash items
1.40B537.00M592.20M581.20M-1.29B1.76B-448.00M276.70M397.20M704.20M91.20M
Operating cash flow
2.25B2.20B2.88B1.55B1.38B3.64B4.23B7.08B6.19B4.55B4.52B
Operating cash flow growth
-8.42%-23.33%+85.85%+11.77%-61.97%-13.95%-40.25%+14.40%+35.96%+0.63%+21.70%
Capital expenditure
—-153.80M-359.80M-311.40M-240.30M-258.10M-424.80M-514.50M-770.60M-867.40M-616.10M
Acquisitions
—0.00-1.07B-6.91B595.00M28.10M0.00179.30M0.000.000.00
Purchases of investments
—-1.26B0.00-5.14B-3.45B-3.81B-7.40B-5.25B-8.16B-5.36B-7.91B
Sales and maturities of investments
—79.70M551.50M8.29B4.66B3.50B7.37B6.49B9.17B5.57B7.38B
Other investing
-5.65B-38.70M83.90M-11.30M24.40M12.90M-26.90M-273.00M-1.50B-1.21B-1.22B
Investing cash flow
-5.50B-1.37B-799.20M-4.09B1.59B-563.70M-608.60M470.50M-2.05B-2.96B-2.48B
Debt issued (repaid)
—-16.90M-650.00M187.30M-1.00B-170.00M1.47B0.00-3.20M-560.90M-2.70M
Shares issued
6.20M-10.00M-31.30M-44.30M-1.90M-700.00K-4.60M0.00-2.10M-5.30M43.70M
Share buybacks
—0.000.000.00-750.00M-1.80B-6.68B-5.87B-4.35B-1.37B-1.00B
Dividends paid
—0.000.000.000.000.000.000.000.000.000.00
Other financing
1.17B-275.00M-2.20M-6.00M-5.60M-115.50M-56.40M7.90M-116.20M-453.70M-28.80M
Financing cash flow
776.60M-301.90M-683.50M137.00M-1.76B-2.09B-5.27B-5.86B-4.47B-2.38B-987.80M
Net change in cash
-2.51B633.50M1.33B-2.37B1.16B930.20M-1.58B1.69B-349.20M-752.70M1.02B
Free cash flow
—2.05B2.52B1.24B1.14B3.38B3.81B6.56B5.42B3.68B3.91B
Free cash flow growth
—-18.48%+103.57%+8.02%-66.17%-11.12%-42.03%+21.17%+47.06%-5.70%+27.11%
Free cash flow margin
—20.73%26.00%12.56%11.25%30.79%28.30%45.65%40.27%30.01%34.12%
Free cash flow per share
—13.9817.248.497.8422.6123.5935.0326.3917.2917.85
Free cash flow per share growth
—-18.92%+103.15%+8.32%-65.34%-4.17%-32.65%+32.75%+52.58%-3.13%+34.32%
Interest paid
——245.40M252.20M262.50M280.80M272.70M————
Income taxes paid
—0.00355.10M740.70M932.90M247.90M906.70M0.000.000.000.00

Figures in USD. Free cash flow is operating cash flow less capital expenditure; owner earnings take off only the spending that keeps the business as it is, not the spending to grow it (an estimate by Financial Modeling Prep). Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Biogen's cash flow

Source: Financial Modeling Prep